European Companies Search Engine
EU funding (€3,992,397): Molecular basis of human enhanceropathies Hor13 Aug 2019 EU Research and Innovation programme "Horizon"
Overview
Text
Molecular basis of human enhanceropathies
Mutations within coding genes have traditionally been considered the major genetic cause of human disease. However, it is becoming increasingly clear that the genetic, structural and/or epigenetic disruption of enhancers and enhancer landscapes represent major etiological factors in numerous human diseases (i.e. enhanceropathies), ranging from rare congenital disorders to common diseases associated with ageing (e.g. cancer, diabetes). Although changes in enhancer activity are predicted to have broad pathological and therapeutic implications, we currently have a limited mechanistic understanding of human enhanceropathies. This reflects, at least partly, our still primitive and partial understanding of the mechanisms whereby enhancers can control gene expression. We hypothesize that enhancers are a diverse group of regulatory sequences that can utilize different mechanisms to control gene expression at the transcriptional and/or post-transcriptional level. Consequently, human enhanceropathies are likely to display an equally diverse molecular basis that, we believe, can only be uncovered using highly multidisciplinary systems biology approaches. Chiefly, elucidating the molecular basis of human enhanceropathies has far reaching translational implications, especially considering the pandemic proportions that some of these disorders are acquiring in recent years. Therefore, the major goal of the ENHPATHY network is to provide early-stage researchers with a multidisciplinary training in which cutting-edge genomic and genetic engineering approaches are ombined with various in vitro and in vivo disease models. Moreover, together with our private partners we aim at translating our molecular findings into new diagnostic and therapeutic strategies.
Funded Companies:
| Company name | Funding amount |
| Advanced Biodesign | €274,802 |
| Annogen B.V. | €265,620 |
| ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE | €281,277 |
| Elvesys | €274,802 |
| EUROPEAN MOLECULAR BIOLOGY LABORATORY | €252,788 |
| Fundacio Centre de Regulacio Genomica | €250,905 |
| GEN-X B.V. | €0.00 |
| Institut National de la Sante et de la Recherche Medicale | €274,802 |
| Istituto Europeo Di Oncologia Srl | €261,500 |
| Kobenhavns Universitet | €297,522 |
| KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW | €265,620 |
| Kungliga Tekniska Hoegskolan | €281,983 |
| Syddansk Universitet | €297,522 |
| Universidad de Cantabria | €250,905 |
| Universita Humanitas | €0.00 |
| Uniwersytet Warszawski | €227,479 |
| Ustav Molekularni Genetiky AV CR V.V.I. | €234,872 |
Source: https://cordis.europa.eu/project/id/860002
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Advanced Biodesign - EU funding (€3,992,397): Molecular basis of human enhanceropathies"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
